In a hearing on Tuesday, Novo Nordisk (NVO) CEO Lars Fruergaard Jørgensen will face questioning from the Senate Committee on Health, Education, Labor, and Pensions about the cost of its GLP-1 drugs, Wegovy and Ozempic.

Yahoo Finance Health Care Reporter Anjalee Khemlani gives a preview of what investors can expect.

For more expert insight and the latest market action, click here to watch this full episode of Market Domination Overtime.

This post was written by Stephanie Mikulich.